These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2214 related items for PubMed ID: 17610808

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 3. Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
    Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.
    Breast Cancer; 2007 Aug; 14(1):81-7. PubMed ID: 17245000
    [Abstract] [Full Text] [Related]

  • 4. Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
    Glück S, Gorouhi F.
    Am J Health Syst Pharm; 2011 Sep 15; 68(18):1699-706. PubMed ID: 21880884
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M, Caruggi M, Colombo G.
    Clin Ther; 2004 Sep 15; 26(9):1546-61. PubMed ID: 15531017
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.
    Am J Manag Care; 2006 Jul 15; 12(7):374-86. PubMed ID: 16834524
    [Abstract] [Full Text] [Related]

  • 9. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov 15; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 10. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
    Karnon J, Delea T, Barghout V.
    Eur J Health Econ; 2008 May 15; 9(2):171-83. PubMed ID: 17602251
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
    Karnon J, Delea T, Johnston SR, Smith R, Brandman J, Sung J, Goss PE.
    Pharmacoeconomics; 2006 May 15; 24(3):237-50. PubMed ID: 16519546
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V.
    Clin Breast Cancer; 2007 Jun 15; 7(8):608-18. PubMed ID: 17592673
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE, El-Ouagari K, Karnon J, Sofrygin O.
    Breast Cancer Res Treat; 2008 Apr 15; 108(3):375-87. PubMed ID: 17653859
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
    Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK, ATAC Trialists' Group.
    Breast Cancer Res Treat; 2007 Dec 15; 106(2):229-38. PubMed ID: 17245540
    [Abstract] [Full Text] [Related]

  • 15. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS.
    Ann Oncol; 2008 Jan 15; 19(1):16-27. PubMed ID: 17693420
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
    Nabholtz JM, Gligorov J.
    Drug Saf; 2006 Jan 15; 29(9):785-801. PubMed ID: 16944964
    [Abstract] [Full Text] [Related]

  • 17. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Skedgel C, Rayson D, Dewar R, Younis T.
    Breast; 2007 Jun 15; 16(3):252-61. PubMed ID: 17207623
    [Abstract] [Full Text] [Related]

  • 18. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Dranitsaris G, Verma S, Trudeau M.
    Am J Clin Oncol; 2003 Jun 15; 26(3):289-96. PubMed ID: 12796603
    [Abstract] [Full Text] [Related]

  • 19. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT, Robert NJ.
    MedGenMed; 2005 Aug 24; 7(3):20. PubMed ID: 16369246
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F, GIM Investigators.
    Lancet Oncol; 2018 Apr 24; 19(4):474-485. PubMed ID: 29482983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 111.